Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse

Emma Tay,1 Wing Kwan Winky Lo,2 Bridin Murnion3 1Drug Health Services, Western Sydney Local Health District, Sydney, NSW, Australia; 2Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; 3Faculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaCorrespondenc...

Full description

Bibliographic Details
Main Authors: Tay E, Lo WKW, Murnion B
Format: Article
Language:English
Published: Dove Medical Press 2022-02-01
Series:Substance Abuse and Rehabilitation
Subjects:
Online Access:https://www.dovepress.com/current-insights-on-the-impact-of-gamma-hydroxybutyrate-ghb-abuse-peer-reviewed-fulltext-article-SAR
_version_ 1818689626630520832
author Tay E
Lo WKW
Murnion B
author_facet Tay E
Lo WKW
Murnion B
author_sort Tay E
collection DOAJ
description Emma Tay,1 Wing Kwan Winky Lo,2 Bridin Murnion3 1Drug Health Services, Western Sydney Local Health District, Sydney, NSW, Australia; 2Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; 3Faculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaCorrespondence: Bridin MurnionDrug Health Services, Western Sydney Local Health District, 4A Fleet Street, North Parramatta, NSW, 2151, Australia, Tel +61 2 9840 3888, Fax +61 2 9840 3927, Email bridin.murnion@sydney.edu.auAbstract: Recreational gamma-hydroxybutyrate (GHB) use, although less common than other substance use, is increasingly recognised and is over-represented in emergency toxicology presentations. This narrative review summarizes GHB pharmacology, current patterns of use, potential harms and management of GHB toxicity and withdrawal. There is a complex interplay between GHB and GABA as GHB is both a prodrug and metabolite of GABA and GHB activates both GHB and GABA receptors. GHB is rapidly absorbed, with effects seen within minutes of ingestion. Metabolism is non-linear at higher doses. While GHB is listed as a controlled substance, its precursor’s gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are easily available as both have industrial applications. National surveys indicate low rates of GHB use, with identification of high-risk populations in men who have sex with men and polysubstance users. GHB is one of the three drugs most commonly used in chemsex. GHB is often co-ingested with other interacting psychoactive substances. Acute toxicity is dose-dependent, and management is supportive care. Withdrawal management is generally with benzodiazepines with addition of baclofen for more severe withdrawal. Barbiturates may have a role. Titration and tapering of pharmaceutical GHB is commonly used in the Netherlands. Complicated withdrawal with delirium may require intensive care and treatment with intravenous sedation. There are high rates of relapse after withdrawal and medications for longer-term management are currently being investigated. Chronic use is associated with poorer mental, physical and sexual health, social dysfunction and poor work performance. Laboratory detection is complicated as GHB is an endogenous substance with a short half-life, and therefore not often routinely assayed in the clinical setting. Future research should focus on improving GHB detection and management of GHB withdrawal and dependence. Interventions specific for high-risk groups should be developed and assessed.Keywords: gamma-hydroxybutyrate, gamma-butyrolactone, 1, 4-butanediol, use, harms, management
first_indexed 2024-12-17T12:13:06Z
format Article
id doaj.art-3e6c6d69a7b84ad9a10266eb760c1daa
institution Directory Open Access Journal
issn 1179-8467
language English
last_indexed 2024-12-17T12:13:06Z
publishDate 2022-02-01
publisher Dove Medical Press
record_format Article
series Substance Abuse and Rehabilitation
spelling doaj.art-3e6c6d69a7b84ad9a10266eb760c1daa2022-12-21T21:49:19ZengDove Medical PressSubstance Abuse and Rehabilitation1179-84672022-02-01Volume 13132372746Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) AbuseTay ELo WKWMurnion BEmma Tay,1 Wing Kwan Winky Lo,2 Bridin Murnion3 1Drug Health Services, Western Sydney Local Health District, Sydney, NSW, Australia; 2Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; 3Faculty of Medicine and Health, University of Sydney, Sydney, NSW, AustraliaCorrespondence: Bridin MurnionDrug Health Services, Western Sydney Local Health District, 4A Fleet Street, North Parramatta, NSW, 2151, Australia, Tel +61 2 9840 3888, Fax +61 2 9840 3927, Email bridin.murnion@sydney.edu.auAbstract: Recreational gamma-hydroxybutyrate (GHB) use, although less common than other substance use, is increasingly recognised and is over-represented in emergency toxicology presentations. This narrative review summarizes GHB pharmacology, current patterns of use, potential harms and management of GHB toxicity and withdrawal. There is a complex interplay between GHB and GABA as GHB is both a prodrug and metabolite of GABA and GHB activates both GHB and GABA receptors. GHB is rapidly absorbed, with effects seen within minutes of ingestion. Metabolism is non-linear at higher doses. While GHB is listed as a controlled substance, its precursor’s gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD) are easily available as both have industrial applications. National surveys indicate low rates of GHB use, with identification of high-risk populations in men who have sex with men and polysubstance users. GHB is one of the three drugs most commonly used in chemsex. GHB is often co-ingested with other interacting psychoactive substances. Acute toxicity is dose-dependent, and management is supportive care. Withdrawal management is generally with benzodiazepines with addition of baclofen for more severe withdrawal. Barbiturates may have a role. Titration and tapering of pharmaceutical GHB is commonly used in the Netherlands. Complicated withdrawal with delirium may require intensive care and treatment with intravenous sedation. There are high rates of relapse after withdrawal and medications for longer-term management are currently being investigated. Chronic use is associated with poorer mental, physical and sexual health, social dysfunction and poor work performance. Laboratory detection is complicated as GHB is an endogenous substance with a short half-life, and therefore not often routinely assayed in the clinical setting. Future research should focus on improving GHB detection and management of GHB withdrawal and dependence. Interventions specific for high-risk groups should be developed and assessed.Keywords: gamma-hydroxybutyrate, gamma-butyrolactone, 1, 4-butanediol, use, harms, managementhttps://www.dovepress.com/current-insights-on-the-impact-of-gamma-hydroxybutyrate-ghb-abuse-peer-reviewed-fulltext-article-SARgamma-hydroxybutyrategamma-butyrolactone14-butanedioluseharmsmanagement
spellingShingle Tay E
Lo WKW
Murnion B
Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse
Substance Abuse and Rehabilitation
gamma-hydroxybutyrate
gamma-butyrolactone
1
4-butanediol
use
harms
management
title Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse
title_full Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse
title_fullStr Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse
title_full_unstemmed Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse
title_short Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse
title_sort current insights on the impact of gamma hydroxybutyrate ghb abuse
topic gamma-hydroxybutyrate
gamma-butyrolactone
1
4-butanediol
use
harms
management
url https://www.dovepress.com/current-insights-on-the-impact-of-gamma-hydroxybutyrate-ghb-abuse-peer-reviewed-fulltext-article-SAR
work_keys_str_mv AT taye currentinsightsontheimpactofgammahydroxybutyrateghbabuse
AT lowkw currentinsightsontheimpactofgammahydroxybutyrateghbabuse
AT murnionb currentinsightsontheimpactofgammahydroxybutyrateghbabuse